Kotoulas, S.C.; Tsiouprou, I.; Fouka, E.; Pataka, A.; Papakosta, D.; Porpodis, K.
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. J. Pers. Med. 2022, 12, 165.
https://doi.org/10.3390/jpm12020165
AMA Style
Kotoulas SC, Tsiouprou I, Fouka E, Pataka A, Papakosta D, Porpodis K.
Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine. 2022; 12(2):165.
https://doi.org/10.3390/jpm12020165
Chicago/Turabian Style
Kotoulas, Serafeim Chrysovalantis, Ioanna Tsiouprou, Eva Fouka, Athanasia Pataka, Despoina Papakosta, and Konstantinos Porpodis.
2022. "Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma" Journal of Personalized Medicine 12, no. 2: 165.
https://doi.org/10.3390/jpm12020165
APA Style
Kotoulas, S. C., Tsiouprou, I., Fouka, E., Pataka, A., Papakosta, D., & Porpodis, K.
(2022). Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. Journal of Personalized Medicine, 12(2), 165.
https://doi.org/10.3390/jpm12020165